Market Access

In the Belgian landscape, Market Access is shaped by a stringent regulatory and reimbursement framework, requiring strategic navigation of FAMHP for market authorization and RIZIV/INAMI for pricing and reimbursement. The system emphasizes health technology assessment (HTA), where clinical and economic value drive decision-making. The focus on cost containment, combined with evolving policies around innovation and real-world evidence, makes the Belgian landscape both challenging and dynamic, and early stakeholder engagement for companies a must.

Healixia has established a Market Access working group since 2025, in response to interest from our members. With this initiative, we aim to strengthen our members professionally by offering training and networking opportunities on different relevant Market Access topics.

We would like to capture which topics are most relevant to Market Access professionals through the short survey below. This will help us tailor our initiatives to the needs and interests of our members.

Topics for future Market Access sessions

Members of the Market Access education group

Erik Present

Erik Present

Benelux Medical Director at Kintiga

Katrien Van Geyt

Katrien Van Geyt

Axes Health BV

Bart Van Den Daele

Bart Van Den Daele

GILEAD Sciences Belgium bv

Stefaan Vansieleghem

Stefaan Vansieleghem

HEBIAS bv

Marlies Boeren

Marlies Boeren

Kintiga

Cédric Libert

Cédric Libert

GILEAD Sciences Belgium bv

Glen Vandyck

Glen Vandyck

GILEAD Sciences Belgium bv

Aline Lescrauwaet

Aline Lescrauwaet

Sandoz nv/sa

Jens Motmans

Jens Motmans

SCS Boehringer Ingelheim Comm.V

Marjan Willaert

Marjan Willaert

pharma.be

Arne Martens

Arne Martens

E&A Pharma

Market Access agenda

  1. DALL·E 2024-10-21 14.09.53 - A visual representation of a medication reimbursement system. The image
    05 June '25

    The new KCE health economics guidelines 2025: how to deal with uncertainties

    Grimbergen

    Join us for an exclusive event dedicated to exploring the upcoming KCE Health Economics (HE) Guidelines for 2025. Discover how these guidelines address key uncertainties and their implications for healthcare decision-making at national and international levels.